Literature DB >> 12504810

Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation.

Konrad F Frank1, Birgit Bölck, Erland Erdmann, Robert H G Schwinger.   

Abstract

The cardiac SR Ca(2+)-ATPase (SERCA2a) regulates intracellular Ca(2+)-handling and thus, plays a crucial role in initiating cardiac contraction and relaxation. SERCA2a may be modulated through its accessory phosphoprotein phospholamban or by direct phosphorylation through Ca(2+)/calmodulin dependent protein kinase II (CaMK II). As an inhibitory component phospholamban, in its dephosphorylated form, inhibits the Ca(2+)-dependent SERCA2a function, while protein kinase A dependent phosphorylation of the phospho-residues serine-16 or Ca(2+)/calmodulin-dependent phosphorylation of threonine-17 relieves this inhibition. Recent evidence suggests that direct phosphorylation at residue serine-38 in SERCA2a activates enzyme function and enhances Ca(2+)-reuptake into the sarcoplasmic reticulum (SR). These effects that are mediated through phosphorylation result in an overall increased SR Ca(2+)-load and enhanced contractility. In human heart failure patients, as well as animal models with induced heart failure, these modulations are altered and may result in an attenuated SR Ca(2+)-storage and modulated contractility. It is also believed that abnormalities in Ca(2+)-cycling are responsible for blunting the frequency potentiation of contractile force in the failing human heart. Advanced gene expression and modulatory approaches have focused on enhancing SERCA2a function via overexpressing SERCA2a under physiological and pathophysiological conditions to restore cardiac function, cardiac energetics and survival rate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504810     DOI: 10.1016/s0008-6363(02)00694-6

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  58 in total

1.  Ouabain binding to Na+,K+-ATPase relaxes cell attachment and sends a specific signal (NACos) to the nucleus.

Authors:  R G Contreras; C Flores-Maldonado; A Lázaro; L Shoshani; D Flores-Benitez; I Larré; M Cereijido
Journal:  J Membr Biol       Date:  2004-04-01       Impact factor: 1.843

Review 2.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure.

Authors:  B M Mayosi; A Kardos; C H Davies; F Gumedze; A Hovnanian; S Burge; H Watkins
Journal:  Heart       Date:  2005-04-21       Impact factor: 5.994

Review 4.  [Reverse remodeling of the intracellular Ca(2+)-homeostasis: new concepts of pathophysiology and therapy of heart failure].

Authors:  Klara Brixius; Konrad F Frank; Birgit Bölck; Felix Hoyer; Robert H G Schwinger
Journal:  Wien Med Wochenschr       Date:  2006-04

5.  Calpain-1 induces endoplasmic reticulum stress in promoting cardiomyocyte apoptosis following hypoxia/reoxygenation.

Authors:  Dong Zheng; Grace Wang; Shuai Li; Guo-Chang Fan; Tianqing Peng
Journal:  Biochim Biophys Acta       Date:  2015-02-04

Review 6.  The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence.

Authors:  E Galli; A Pingitore; G Iervasi
Journal:  Heart Fail Rev       Date:  2008-12-27       Impact factor: 4.214

7.  Enhanced L-type calcium currents in cardiomyocytes from transgenic rats overexpressing SERCA2a.

Authors:  Andre Kamkin; Irina Kiseleva; Heinz Theres; Jaime-Jürgen Eulert-Grehn; Kay-Dietrich Wagner; Holger Scholz; Roland Vetter
Journal:  Exp Clin Cardiol       Date:  2010

8.  Progesterone modulates SERCA2a expression and function in rabbit cardiomyocytes.

Authors:  Karni S Moshal; Zhe Zhang; Karim Roder; Tae Yun Kim; Leroy Cooper; Bogdan Patedakis Litvinov; Yichun Lu; Vishal Reddy; Dmitry Terentyev; Bum-Rak Choi; Gideon Koren
Journal:  Am J Physiol Cell Physiol       Date:  2014-09-24       Impact factor: 4.249

Review 9.  Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?

Authors:  Hashim Khan; Marco Metra; John E A Blair; Mark Vogel; Matthew E Harinstein; Gerasimos S Filippatos; Hani N Sabbah; Herve Porchet; Giovanni Valentini; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-02-24       Impact factor: 4.214

Review 10.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.